Future Phase 3 DUO-E Subgroup Data May Prove ‘Intriguing’ in Endometrial Cancer
Future analyses will look at durvalumab/olaparib for endometrial cancer populations with TP53 and POLE alterations, as well as those with estrogen receptor and progesterone receptor positivity.
Following readout of data from the phase 3 DUO-E/GOG-3041/ENGOT-EN10 trial (NCT04269200)—assessing combination chemotherapy/durvalumab (Imfinzi), single-agent durvalumab, and durvalumab/olaparib (Lynparza) in patients with newly diagnosed advanced or recurrent endometrial cancer —Shannon N. Westin, MD, MPH, FACOG, discusses future analyses focused around outcomes in select molecular subgroups.
In an interview with CancerNetwork® during the 2023 Annual Global Meeting of the International Gynecologic Cancer Society (IGCS), Westin, a professor in the Department of Gynecologic Oncology and Reproductive Medicine in the Division of Surgery at The University of Texas, MD Anderson Cancer Center, detailed next steps for the study including quality-of-life studies and readouts of more mature data. In particular, she highlighted that The Cancer Genome Atlas will be used to assess outcomes in those TP53 of POLE alterations, as well as those with estrogen receptor– and progesterone receptor–positive endometrial cancer.
Transcript:
From the standpoint of what we're going to look at, we have, as I mentioned, quality-of-life studies planned. We're looking at other key secondary markers, like progression free survival (PFS) 2, and we're waiting for the overall survival (OS) to mature. There are certainly a lot of further analyses of these data, but I think I'm most intrigued and excited about the opportunities to do some more of the deep dive molecular studies.
[This will be] specifically looking at the Cancer Genome Atlas [TCGA] classification, looking at things like TP53, the POLE population, and the population that has [estrogen receptor] ER and [progesterone receptor] PR positivity. There are a lot of opportunities to tease out the group that benefits the most. From a bottom-line standpoint, I'm very hopeful that these drugs will soon be available for our patients.
Reference
Westin SN, Moore KN, Chon HS, et al. DUO-E/GOG-3041/ENGOT-EN10 trial: carboplatin/paclitaxel + durvalumab followed by maintenance ± olaparib as first-line treatment for newly diagnosed advanced or recurrent endometrial cancer. Presented at the 2023 Annual Global Meeting of the International Gynecologic Cancer Society; November 5-7, 2023; Seoul, South Korea.
Frontline Chemo-Free Regimen Supported in HR+/HER2+ Breast Cancer Therapy
January 1st 2024Combining anastrozole with palbociclib, trastuzumab, and pertuzumab as a frontline therapy for hormone receptor–positive, HER2-positive breast cancer may avoid some of the toxicities associated with chemotherapy, says Amy Tiersten, MD.
Oncology On-The-Go Podcast: ASCO 2023 Recap
June 19th 2023Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.
